Cargando…

Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches

Antiplatelet agents, with aspirin and P2Y(12) receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral artery diseases. Over the last decades, significa...

Descripción completa

Detalles Bibliográficos
Autores principales: Jourdi, Georges, Godier, Anne, Lordkipanidzé, Marie, Marquis-Gravel, Guillaume, Gaussem, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832164/
https://www.ncbi.nlm.nih.gov/pubmed/35155631
http://dx.doi.org/10.3389/fcvm.2022.805525
_version_ 1784648667477573632
author Jourdi, Georges
Godier, Anne
Lordkipanidzé, Marie
Marquis-Gravel, Guillaume
Gaussem, Pascale
author_facet Jourdi, Georges
Godier, Anne
Lordkipanidzé, Marie
Marquis-Gravel, Guillaume
Gaussem, Pascale
author_sort Jourdi, Georges
collection PubMed
description Antiplatelet agents, with aspirin and P2Y(12) receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral artery diseases. Over the last decades, significant changes have been made to antiplatelet therapeutic and prophylactic strategies. The shift from a population-based approach to patient-centered precision medicine requires greater awareness of individual risks and benefits associated with the different antiplatelet strategies, so that the right patient gets the right therapy at the right time. In this review, we present the currently available antiplatelet agents, outline different management strategies, particularly in case of bleeding or in perioperative setting, and develop the concept of high on-treatment platelet reactivity and the steps toward person-centered precision medicine aiming to optimize patient care.
format Online
Article
Text
id pubmed-8832164
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88321642022-02-12 Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches Jourdi, Georges Godier, Anne Lordkipanidzé, Marie Marquis-Gravel, Guillaume Gaussem, Pascale Front Cardiovasc Med Cardiovascular Medicine Antiplatelet agents, with aspirin and P2Y(12) receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral artery diseases. Over the last decades, significant changes have been made to antiplatelet therapeutic and prophylactic strategies. The shift from a population-based approach to patient-centered precision medicine requires greater awareness of individual risks and benefits associated with the different antiplatelet strategies, so that the right patient gets the right therapy at the right time. In this review, we present the currently available antiplatelet agents, outline different management strategies, particularly in case of bleeding or in perioperative setting, and develop the concept of high on-treatment platelet reactivity and the steps toward person-centered precision medicine aiming to optimize patient care. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8832164/ /pubmed/35155631 http://dx.doi.org/10.3389/fcvm.2022.805525 Text en Copyright © 2022 Jourdi, Godier, Lordkipanidzé, Marquis-Gravel and Gaussem. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Jourdi, Georges
Godier, Anne
Lordkipanidzé, Marie
Marquis-Gravel, Guillaume
Gaussem, Pascale
Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
title Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
title_full Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
title_fullStr Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
title_full_unstemmed Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
title_short Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
title_sort antiplatelet therapy for atherothrombotic disease in 2022—from population to patient-centered approaches
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832164/
https://www.ncbi.nlm.nih.gov/pubmed/35155631
http://dx.doi.org/10.3389/fcvm.2022.805525
work_keys_str_mv AT jourdigeorges antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches
AT godieranne antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches
AT lordkipanidzemarie antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches
AT marquisgravelguillaume antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches
AT gaussempascale antiplatelettherapyforatherothromboticdiseasein2022frompopulationtopatientcenteredapproaches